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A NOVEL THERAPY FOR BREAST CANCER: 
IMPLICATIONS FOR TREATMENT ACCESS 
OMAR CESPEDES-GOMEZ 
ABSTRACT 
 In 2016, there were 250,000 new cases of invasive cancer and 60,000 of 
ductal carcinoma in situ. Mammograms are used to screen for cases of disease, 
but the literature shows that mammograms are highly dependent on patient 
characteristics and do not majorly impact mortality rates from invasive cancer. 
Additionally, they are prone to false-positives, false-negatives, and overdiagnosis 
in cases of in situ cancer, with overdiagnosis exposing patients to the side effects 
of treatment. Better screening tests are needed, and a potential solution can be to 
extend molecular screening methods often used in advanced stage 1 and higher 
cancers to stage 0 ductal carcinoma in situ cases. This new test would prevent 
overdiagnosis, be more accurate, and prevent unnecessary screening as well as 
be in line with the future of cancer care in the US. 
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INTRODUCTION 
Breast cancer continues to be a health concern in the United States. Newly 
diagnosed cases of breast cancer, the most commonly diagnosed cancer in 
women, is more than the sum of the second and third most diagnosed cancers, 
which are colorectal and cervical cancer (Hortobagyi et al., 2005)., de la Salazar, 
& Pritchard, 2005). In 2014, breast cancer accounted for approximately 29% of 
new cancers diagnosed, and among women afflicted with cancer, breast cancer 
was the leading cause of death in the 20-59 age group (Siegel et al., 2015)). 
Moreover, the chance of a woman developing breast cancer in their lifetime is 
one in nine (Siegel et al., 2015). In 2016, 61,000 cases in ductal carcinoma in situ 
(DCIS), 246, 600 cases of invasive disease, and 40,450 deaths are expected 
(American Cancer Society, 2016). 
 
Epidemiological Burden of the Disease 
Worldwide, the breast cancer burden is massive with 7.6 million people 
dying of cancer in 2005 (Morabia & Abel, 2006). Incidence and mortality of breast 
cancer differs greatly between industrialized and developing countries 
(Hortobagyi et al., 2005).  Cancer burden is growing in poorer countries because 
of increases in life expectancy, greater deaths due to smoking and obesity, and 
		 2 
decreases in death from infectious diseases (Morabia & Abel, 2006). More than 
half of new breast cancer cases occur in industrialized countries like the USA, 
while three quarters of breast cancer mortality occurs in the developing world 
(Hortobagyi et al., 2005). The difference in these epidemiological factors can be 
attributed to lack of mammographic screenings in underdeveloped countries, 
late stage of diagnosis in these countries, poor access to care, and below average 
treatment regimes (Smith et al., 2006).  This literature review only considers 
breast cancer epidemiology in the United States. 
In the United States, the National Cancer Institute (NCI) is the federal 
organization responsible for addressing research and training for the cause, 
diagnosis, and treatment of cancer, and thus it is an important institution in the 
fight against cancer (Hankey et al., 1999).  Since 1973, the NCI has provided 
monitoring of new cancer cases to assess the impact of new prevention, 
screening, and treatment strategies through the Surveillance, Epidemiology, and 
End Results Program, or SEER (Hankey et al., 1999). Data is collected from 
population-based registries on stage of cancer at time of diagnosis, tumor site, 
survival data, patient demographics, and survival (Hankey et al., 1999). From 
1973 to 2003, registries covered 10% of the United States population, and there 
has been an expansion of the scope of surveillance to cover 23% of the United 
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States population (Hayat et al., 2007). So, despite the fact that it only covers a 
portion of the US, SEER is a valuable program in assessing breast cancer trends 
and is a source of statistical information in this literature review. 
Through the national health interview survey breast cancer screenings can 
be tracked. The national health interview survey (NHIS) is an annual survey 
administered jointly by the National Cancer Institute and Centers for Disease 
Control and Prevention, and the NHIS has found that use of mammograms for 
screening has increased from 29% in 1987 to 75% in 2000 (Swan et al., 2003). 
Increases in mammographic screenings are a result of the preventive 
practices set for by the US Preventive Task Force. The US Preventive Task Force 
was established in 1984, and its role is to review the scientific evidence for 
clinical preventive services, and to make recommendations to primary care 
physicians on what procedures should be implemented in regular examinations 
(Woolf, 1992). Currently, the US Preventive Task Force calls for annual breast 
examinations to women after 40 years of age, mammography every 1 to 2 years 
after age of 50, and increased screening for women at higher risk for breast 
cancer. 
In theory, increased adoption of breast cancer screening would lead to an 
increase in cancers detected such that there are higher incidences of low risk 
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cancers, lesions that are premalignant, and ductal carcinoma in situ. As a matter 
of fact, ecologic studies in the United States show an increase in ductal carcinoma 
in situ and premalignant breast cancers starting in 1970 with the increased 
adoption of screening mammograms. According to the SEER, in 1980 there were 
102.3 new cases of breast cancer per 100,000 females and 31.7 deaths per 100,000 
people (Clegg et al., 2002). However in 2012, 129.6 new cases of breast cancer per 
100,000 people, and 21.3 deaths were recorded. As can be seen, deaths have not 
changed significantly since 1980, though it might be expected that increased 
screening would lead to a reduction in reduced cancer rates. So, the lack of a 
drop in cancer incidence rates might suggest that breast screenings are only 
detecting clinically insignificant cancers and screening might also be causing 
overdiagnosis and overtreatment (Altekruse et al., 2010; Haas etl al,  Kaplan et 
al., 2004; Johnson & Shekhdar, 2005). 
Specifically, since 1990, breast cancer incidence rates increased for women 
aged 50-74 as a result of greater screening practices, while cancer mortality 
decreased very little though there was a greater use of hormonal and cytotoxic 
treatments during this time period (Peto et al., 2000, Boreham et al., 2000; Peto, 
2000).  
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Breast cancer continues to be the leading cause of death amongst women 
(Murray & Lopez, 1997) though physiological functions impact how the disease 
develops. It has been found that breast cancer incidence increases with age in 
premenopausal women in comparison with postmenopausal women. 
Specifically, there is a reduction in the relative risk of breast cancer five years 
after menopause, with a decrease of 2.5% in the relative risk every year after that. 
In all, breast cancer cumulative incidence in the United States is 2.7% at 55, 5% at 
65, 7.7% by 75 which represents a slower increase in incidence in comparison to 
premenopausal years where cumulative incidence increases rapidly (“Breast 
cancer and hormone replacement therapy,” 1997; Key et al., Verkasalo, & Banks, 
2001). Thus, breast cancer relative risk and incidence has changed as diagnostic 
and treatment technologies become available, and the epidemiologic endpoints 
of the disease vary by age group. Currently, many prevention strategies for the 
disease are being undertaken, and there are also many new treatment options 
with many more appearing through the pipeline.  
Staging and DCIS 
Staging involves the process of determining where the cancer has spread 
locally inside the breast or to other parts of the body. The stage of the breast 
cancer, a result of tests done on the tumor and lymph nodes, will determine the 
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treatment progression for breast cancer patients. The American Joint Committee 
on Cancer (AJCC) stages breast cancer based on a description of the tumor, 
lymph node status, and metastasis. The stages of breast cancer are shown in 
Table 1 (Singletary et al., 2002; Woodward et al., 2003).  
 Stage 0 is the lowest stage of breast cancer and it represents ductal 
carcinoma in situ ( DCIS) , which is a noninvasive condition. When a pathologist 
looks at a breast biopsy with stage 0, the pathologist will note how different 
abnormal cells look from normal cells, and decide if the cells appear as DCIS or 
invasive breast cancer (Figure 1). DCIS can be categorized further into 
micropapillary, papillary, solid, cribiform, and comedo type. Comedo-type DCIS 
appears to be the most likely to advance to invasive ductal carcinoma. 
Pathologically, comedo-type DCIS appears with central necrosis, and nuclear 
pleiomorphism. Figure 2 shows the pathology of comedo-type DCIS.  
 
This paper will focus on DCIS because DCIS diagnosis, as stated before, has 
increased since screening mammography has become widespread, and this is 
believed to have lead to an increase in overdiagnosis and overtreatment of breast 
cancer. Overtreatment is just one unintended consequence of mammography 
screening, and this problem can be mitigated with the development of better 
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screening tests.  (“Diagnosis of DCIS,” 2015; Fonseca et al., 1997a; Welch & Black, 
2010a). 
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Figure 1:  Malignancy of Normal Cells to Invasive Cancer in the Breast Duct 
Source: (“Diagnosis of DCIS,” 2015). 
 
 
 
		 9 
Figure 2: Comedo type Ductal Carcinoma in Situ 
Source: (“Diagnosis of DCIS,” 2015). D represents the normal cells of the ducts 
that make up breast lobules. Letters and A and B represent metaplasia of the 
cells, and C represents necrosis, or death, of the central-most breast duct cells. 
This is a result of the rapid growth of cells A and B which starve the cells in 
region C of oxygen and nutrients that leaves large areas of cell death (“Diagnosis 
of DCIS,” 2015). 
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Table 1: AJCC Breast Cancer Staging 
Stage Description 
Stage 0 
• Breast Carcinoma in Situ which involves ductal carcinoma in 
situ (DCIS), lobular carcinoma in situ ( LCIS), and paget 
disease of the nipple. 
Stage IA 
• The tumor has not spread outside the breast and the tumor is 
2cm or smaller. 
Stage IB 
• The tumor is 2cm or smaller, and a small number of breast 
cancer cells are found in the lymph nodes. 
Stage IIA 
• No tumor found in the breast and cancer cells are found in 
axillary lymph nodes, OR 
• The tumor size is less than 2cm and found in 1 to 3 lymph 
nodes, OR 
• The tumor is larger than 2cm but not larger than 5 cm 
Stage IIB 
• The tumor is greater than 2cm and smaller than 5cm and a 
small number of cancer cells are found in the lymph nodes, 
OR 
• The tumor is larger than 2cm and smaller than 5cm and a 
breast cancer cells are found in 1 to 3 lymph nodes, OR 
• The tumor is larger than 5 cm, but no cancer cells are found 
in the lymph nodes. 
Stage IIIA 
• No tumor found in the breast/ the tumor can be of any size 
and breast cancer cells are found in 4 to 9 lymph nodes in the 
axilla. 
• The tumor is larger than 5cm and breast cancer cells are 
found in the lymph nodes. 
• The tumor is larger than 5cm and breast cancer cells are 
found 1 to 3 lymph nodes. 
Stage IIIB 
• The tumor is any size and breast cancer cells have spread to 
the chest and caused an ulcer.  
Stage IIIC 
• No tumor is present/tumor can be any size and breast cancer 
cells can be found in 10 or more lymph nodes. 
Stage IV 
• The cancer has spread to other part of the body such as to the 
liver or bones 
Source: (“Breast Cancer Treatment,” n.d.; S. E. Singletary et al., 2002; Woodward 
et al., 2003). 
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PUBLISHED STUDIES 
Considering the epidemiological burden and the problem of overdiagnosis of 
breast cancer, it is important to consider the risks for breast cancer. Studies 
undertaken have looked at numerous risk factors. Thus far, in the literature, 
there are reproductive, lifestyle, and genetic risk factors that should be 
considered when evaluating a woman’s risk for breast cancer. Addressing these 
risk factors should decrease a woman’s risk. 
Genetic Factors 
 Genetic factors and lifestyle factors play an important role in breast cancer 
development. Studies of twins make it possible to determine the effects of genes 
on the development of cancer. In a study in 3 Nordic countries involving 45,000 
pairs of twins, it was determined that 27% of breast cancer had some form of 
genetic component (Key et al., 2001). This is just a minor component in breast 
cancer development as 73% of breast cancers were due to lifestyle factors (Key et 
al., 2001; Pharoah et al., 1997). 
In terms of the familial component of breast cancer, it is known that breast 
cancer is more common in families that have a history of the disease. This 
phenomenon has even been described as early as 1866, and epidemiologic 
studies have determined that there is an elevated risk, almost two-fold for 
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individuals with first-degree relatives affected by the disease (Pharoah et al., 
1997). Of course, individuals with second-degree relatives suffering from the 
disease have a lower risk for breast cancer malignancies. This risk applies to 
women diagnosed with breast cancer before the age of 50 (Key et al., 2001; 
Pharoah et al., 1997). 
Genetically, numerous germ-line mutations have been identified which 
predispose women to breast cancer, and these mutations have been identified 
through family-based studies and population-based studies. Mutations in alleles 
including BRCA1, BRCA2, PTEN, and P53 account for 5% of cancer cases and 
about 25% family-related breast cancers overall (Key et al., 2001; Pharoah et al., 
1997). From population studies in Iceland, it was estimated that women with the 
BRCA2 mutation 999del5 was 37% by age 70, and from studies of Ashkenazi 
Jews it was estimated that mutations in BRCA1 and BRCA2 (185 delAG , 5382ins 
C, and 617delT mutations) by age 70 led to a 56% change of breast cancer (Key et 
al., 2001; Pharoah et al., 1997). These rates are lower than rates determined by 
family-based studies, and it is believed that family based studies overestimate 
breast cancer risks because of bias associated with such research: family-based 
studies only look for families with high breast cancer risks. From this data, it is 
unlikely that these germ-line mutations contribute significantly to breast cancer 
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rates for women over age 70, and it is believed that other lower-risk mutations 
drive breast cancer risk in this age group (Key et al., 2001; Pharoah et al., 1997) 
Reproductive Risk Factors 
 Reproductive factors play a role in risk of breast cancer. These include, age 
at menarche, age of menstruation, and age at first pregnancy. The younger the 
age of menarche, the higher the risk for breast cancer, or the older a woman at 
first menarche the lower the risk of breast cancer. This effect is more pronounced 
in younger women, and it has been found that for every 1 year in delay of 
menarche there is a decreased risk of breast cancer of 5% (Hunter et al., 1997; 
Kelsey et al., 1993). Conversely, the higher the age of menopause, the higher the 
risk of breast cancer such that for every 5-year change in menopause, there is a 
17% difference in breast cancer risk. It has been shown that early menarche leads 
to higher levels of total life-time estrogen in women, and thus the effects of early 
menarche and late menopause seem to implicate sex hormones in breast cancer 
risk such that longer years exposed to sex hormones increase the risk of breast 
cancer (Hunter et al., 1997; Kelsey et al., 1993). 
 From a biochemical perspective, estradiol stimulates the breast cancer 
epithelial cells to proliferate, which provides a mechanism for how increased 
lifetime exposure to this hormone increases breast cancer risk. A decrease in the 
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level of ovarian hormone production has been determined to play a role in the 
diminished risk of breast cancer as oestrogens in post-menopausal women 
decrease. Evidence of estradiol’s effects on breast cancer can be seen in post 
menopausal women taking hormone replacement therapy (HRT). In women 
undergoing HRT, estradiol levels are higher as compared to post-menopausal 
women who are untreated. This leads to a small increase in breast cancer risk, 
and the effects of HRT on breast cancer may be even greater if progesterone is 
administered as well (Key et al., 2001). 
Studies have shown a positive association with progesterone, but these 
effects have recently been questioned considering studies of women taking oral 
contraceptives (Russo & Russo, 1998). In women taking oral contraceptives, 
endogenous estradiol and progesterone are replaced by exogenous sources of 
these hormones, and while estradiol levels remain the same, women are exposed 
to higher levels of progesterone. Nonetheless, breast cancer rates in women 
taking oral contraceptives are similar to those in  women with natural menstrual 
cycles. 
Pregnancy is an interesting case because short-term, breast cancer risk 
increases while long-term there is a decrease in breast cancer risk. In pregnancy, 
high estradiol concentrations stimulate proliferation of breast cancer cells, but 
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other pregnancy hormones stimulated breast epithelial cells to differentiate into 
glandular-like cells. It has been found that one pregnancy decreases breast cancer 
risk by 25%, and multiple pregnancies enhance the effects of pregnancy on breast 
cancer reduction (Russo & Russo, 1998).  
Diet 
 Animal studies as well as an international comparison investigation 
involving a meta-analysis of published case-control studies have all pointed to 
the effect of high dietary fat as a risk factor for breast cancer in post-menopausal 
women (Howe et al., 1990). The attributable risk, or the percentage of breast 
cancer cases that were attributed to high fat content, was 24% for 
postmenopausal women and 15% for premenopausal women (Howe et al., 1990).  
These studies supported the hypothesis that high dietary fat may be a risk 
factor for breast cancer, however, in cohort studies, which are less prone to 
particular study biases, no such evidence was found (Hunter et al., 1996; Key et 
al., 2001). In a 1996 study published in the New England Journal of Medicine, 
women in a quintile with high fat intake were compared to women with low fat 
intake, and it was found that there was no association between dietary fat intake 
and breast cancer risk (Hunter et al., 1996; Key et al., 2001) . Moreover, women 
who consumed less dietary fat had no less of a risk for breast cancer. However, it 
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is important to note that this study relied on study questionnaires to assess total 
dietary fat intake. Thus, these results must be interpreted with caution. (Hunter 
et al., 1996; Key et al., 2001). 
In another cohort study conducted in 1999, a total of 88,795 women were 
followed for 14 years beginning in 1976 (Holmes et al., 1999). Of these women, 
2956 were diagnosed with breast cancer. Women with high fat content, in which 
between 30 % and 35% of their total diet was fat, were compared to women who 
had a lower dietary fat intake. These women obtained less than 20% of their daily 
calories from fat. It was found that women who had high fat diets did not have 
any higher increased risk of developing breast cancer when compared to women 
with low fat diets (Holmes et al., 1999).  Though it seems that fat intake does not 
lead to increased risks of breast cancer, the American Cancer Society ( ACS) 
makes important recommendations regarding nutrition and exercise that should 
be considered so women decrease their risk for breast cancer. 
Exercise 
Exercise reduces breast cancer risk, according to various published articles 
(refs). However, results vary as a study on physical activity and breast cancer 
examined 21 individual studies. 15 studies support a reduction in physical 
activity to mitigate breast cancer risk, 4 studies resulted inconclusive, and 2 
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studies supported an increase in breast cancer as a result of physical activity 
(Friedenreich et al., 1998; Key et al., 2001). Of the studies that showed a reduction 
in breast cancer, it was determined that a few hours of exercise per day showed a 
reduction of 30% of physical activity. Moreover, women who had a leaner BMI 
benefitted more from exercise as compared to women with higher BMIs. It has 
yet to be determined if the effects of physical activity on breast cancer are due to 
energy balance, hormone maintenance, or immune system strengthening 
(Friedenreich et al., 1998; Key et al., 2001). 
Alcohol 
In terms of modifiable behavior, alcohol consumption has been argued to 
be a risk factor for breast cancer (Key et al., 2001; Singletary & Gapstur, 2001). 
Many studies have been undertaken, but there have been mixed results on the 
correlation between alcohol consumption and breast cancer (Key et al., 2001; 
Singletary & Gapstur, 2001). A Journal of the American Medical Association 
study published in 1998 sought out to delineate this relationship as 6 
retrospective cohort studies were analyzed in which a total of 322,000 women 
were followed for 11 years (Key et al., 2001; Singletary & Gapstur, 2001). It was 
found that with intake of less than 60g of alcohol per day, risk increased in a 
linear fashion; 10 g/day of alcohol increases breast cancer risk 10% and 30g/day 
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of alcohol increases breast cancer risk by 30%. However above 60 grams per day, 
there was no greater increase in breast cancer risk (Key et al., 2001; Singletary & 
Gapstur, 2001). So, alcohol consumption is associated with moderately increased 
rates of breast cancer. This means that women who consume alcohol can see their 
risk of breast cancer reduced if alcohol consumption is diminished (Key et al., 
2001; Singletary & Gapstur, 2001). 
Breast Cancer Risk Summary 
From the presented studies, it can be concluded that the contribution of 
genes to breast cancer is minimal as compared to lifestyle factors. Nonetheless, 
women with susceptible gene mutations are at a higher risk for breast cancers, 
and women with these mutations, whose family suffers from higher breast 
cancer rates, should determine which mutations they are most prone to. It is 
currently impossible to correct gene mutations, so women should look to 
minimizing their risk through lifestyle changes. Reproductive risk factors in 
breast cancer may be hard to control because women have limited control of 
their body’s biological progression as they age. When contemplating HRT to 
alleviate the symptoms of menopause, women should weigh their risks and 
benefits of the therapy with their physician. In terms of dietary factors and 
exercise, the literature and published studies are inconclusive, though it is still 
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important to maintain a healthy lifestyle and adequate nutrition to mitigate risks 
for other diseases. Alcohol should also be limited in women who consume 
moderate amounts of alcohol, as published studies show that a decrease in this 
quintile of alcohol consumption can reduce breast cancer risk.  
Screening 	 Evaluating lifestyle and genetic components is a good start to minimizing 
cancer risk. It is still essential to diagnose breast cancer in its early stages. Often 
when breast cancer is found, the cancer is large and most likely to have 
metastasized outside of the breast tissue (“American Cancer Society | 
Information and Resources for Cancer: Breast, Colon, Lung, Prostate, Skin,” 
2016). Approximately 5% to 15% of breast cancers diagnosed have metastasized, 
and 40% have spread regionally, so treatments are ineffective because they are 
started too late (“American Cancer Society | Information and Resources for 
Cancer: Breast, Colon, Lung, Prostate, Skin,” 2016; Vogel, 2000). So, screening 
exams are an important way to identify cancers before they start to cause 
symptoms in women (“American Cancer Society | Information and Resources 
for Cancer: Breast, Colon, Lung, Prostate, Skin,” 2016).  
In order to diagnose breast cancer, several methods are utilized. Self-
breast examinations are an important component of diagnosing breast cancer at 
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an early stage. When performing self-breast examinations, it is essential for 
women to know how their breasts normally look and feel. In this manner, it 
easier to note important changes in their body in order to identify cancer as early 
as possible while conducting self breast exams. Most commonly, breast cancer 
presents with a mass or a lump, and painless hard masses that have irregular 
edges have a greater chance of being cancerous.  However, it is very possible for 
breast cancers to be painful, soft and even spread to lymph nodes found under 
the arm or collarbone and cause swelling even though the tumor might not be 
apparent in the breast tissue. So, women should also be aware of any enlarged or 
swollen lymph nodes, and breast masses should be checked by health care 
providers that are experts in diagnosing breast cancer. It is important to note that 
knowing what to look for in self-exams does not replace regular mammograms 
by physicians. (“American Cancer Society | Information and Resources for 
Cancer: Breast, Colon, Lung, Prostate, Skin,” 2016, Semiglazov et al., 2003; 
Thomas et al., 2002). Table 2 presents other symptoms of breast cancer. 
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Table 2: Symptoms of Breast Cancer 
Symptoms 
§ Swelling of all or part of a breast (even if no distinct lump is felt) 
§ Skin irritation or dimpling 
§ Breast or nipple pain 
§ Nipple retraction (turning inward) 
§ Redness, scaliness, or thickening of the nipple or breast skin 
§ Nipple retraction (turning inward) 
Source: (“American Cancer Society | Information and Resources for Cancer: 
Breast, Colon, Lung, Prostate, Skin,” 2016) 
 
 Studies evaluating breast self examinations (BSE) have not shown 
that they reduce breast cancer mortality significantly.  In a 2002 published study, 
266, 064 women in Shanghai, China were randomly assigned to a breast self 
examination (Thomas et al., 2002). The women in the BSE group practiced BSE 
every six months under medical supervision for 5 years, and they were 
subsequently followed up until 2000. In terms of deaths due to breast cancers, 
there were 135 deaths in the instruction group and 131 deaths in the control 
group. Additionally, more benign and smaller breast lesions were found in the 
BSE group as compared to the control group (Thomas et al., 2002). From this 
study it was subsequently determined that BSE does not significantly reduce 
breast cancer mortality (Thomas et al., 2002).  
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 Other screening methods are performed in the clinic. These include first, a 
physical exam and history where a provider checks patients’ general health. 
General physical exams include an inventory of patients’ current and past health, 
illnesses, and treatments. A clinical exam is next, and this is as a more focused 
exam. This involves the provider examining and feeling the arms and breasts for 
lumps and unusual findings. Clinical breast exams have not been compared to 
BSE, thus, there is a gap in the literature as to the effectiveness of clinical breast 
exams in reducing breast cancer mortality (“Breast Cancer,” 2016). A subsequent 
Nelson et al. study also found that there was no clinical benefit for clinical breast 
exams or self breast examinations (Nelson et al., 2009), so the question remains; 
are BSE and clinical breast exams important for reducing breast cancer risk ? It is 
still recommended that though BSE and clinical breast exams do not reduce 
mortality significantly, they are crucial in early diagnosis because they alert 
providers to cases that need monitoring. 
Mammograms 
 Screening mammograms performed on asymptomatic women 
decreases breast mortality as well (“Breast Cancer,” 2016). A study released in 
2009 aimed to update with solid evidence the US Preventative Service Task Force 
(USPSTF) 2002 recommendations of screening every 1 to 2 years for women over 
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the age of 40. The study contributed to knowledge in favor of providing 
mammograms for women in the 40 to 49, and for the 70 and older group. Using 
two high quality databases, the investigators pinpointed high quality 
randomized control trials from which they could extract and analyze the relevant 
data. They found that, indeed, mammograms cause a decrease in mortality of 
15% if they are between the ages of 30 and 39 (Moss et al., 2006). 
 Another study, The Age Trial study, sought to further investigate the 
potential influence of including older women in studies of the benefits of 
mammogram on breast cancer mortality (Moss et al., 2006). Moss et al. analyzed 
160,921 women ranging from ages 39 to 41 who were randomly assigned to an 
annual mammography group until the age of 48. This study found that though 
there was a reduction in breast cancer mortality, it was not statistically 
significant. The absolute mortality benefit was 1% (Moss et al., 2006). This was a 
surprising result considering the emphasis placed on mammograms as important 
tools for preventing cancer. 
 A 2014 study further cast doubts on screening mammograms (Miller et al., 
2014). The study presented 25 year follow up results comparing women aged 40-
59 who underwent mammography screening in comparison to women who did 
not undergo mammography screening. The study based in Canada involved 15 
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centers and 89,835 women. They found that 666 cancers where diagnosed with 
mammography and 524 without mammography. 180 women died in the 
mammography group and 171 in the control group. Moreover, it was determined 
that over diagnosis occurred in 1 case for every 424 women who received 
screenings. So, in this study it was concluded that annual mammography does 
not significantly reduce breast cancer (Miller et al., 2014). For example, treating a 
fast-growing, aggressive cancer may not be effective despite the fact that it was 
detected on mammography.  
Mammograms are screening tests for breast cancer in which an x-ray of 
the breast tissue is taken. A screening test consists of 2 images taken of each 
breast such that there is a cranio caudal (CC) view from above and a mediolateral 
oblique (MLO), or angled view, of each breast  (Figure 3). There are 2 types of 
mammograms: screening mammograms and diagnostic mammograms. In 
screening mammograms, x-rays are taken of breast tissue from two different 
angles. Diagnostic mammograms conversely, can involve x-rays taken from 
multiple angles if screening mammograms show suspicious test results, and may 
even be used for patients who were treated for breast cancer in the past. It is 
important to note that mammograms cannot be used to diagnose breast cancer as 
additional tests are needed for an accurate diagnosis (“Mammograms,” 2014) 
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(“US Food and Drug Administration Home Page,” 2016) 
 Mammograms can either be standard, digital, and even 3D. Standard 
mammograms are printed on large sheets of film while digital mammograms are 
captured, stored, and saved in a digital fashion. Finally, 3D mammography is an 
innovation from standard or digital mammograms as it involves the x-ray 
machine capturing numerous images of the breast from different angles. This 
allows the system to construct a 3 dimensional view of the breast that diminishes 
the chance of being called back for a mammogram due to inaccurate testing. 
Advanced mammograms like those described may not be available to everyone, 
so patients should not forego mammograms even though digital mammograms 
or 3D mammograms may not be available (“American Cancer Society | 
Information and Resources for Cancer: Breast, Colon, Lung, Prostate, Skin,” 2016, 
“Mammograms,” 2014)  
From a clinical perspective, two breast changes can be seen on 
mammograms, and these are calcifications and breast masses. Calcifications are 
mineral deposits in breast tissue that are viewed as small white spots that 
present as either macrocalcifications or microcalcifications. Depending on the 
type of calcification, a biopsy may be needed to confirm or rule out breast cancer 
(“American Cancer Society | Information and Resources for Cancer: Breast, 
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Colon, Lung, Prostate, Skin,” 2016, “Mammograms,” 2014). 
Macrocalcifications  (Figure 4, Figure 5), are coarse calcium deposits that 
are caused from normal changes in breast tissue due to aging, injuries, and even 
inflammation. Macrocalcifications present as large white dots on mammograms, 
and are almost always non cancerous. These findings do not need further inquiry 
as they are found in 50% of women over the age of 50 and in 10% of women 
under the age of 50 (“Mammograms,” 2014).  
Microcalcifications (Figure 6,  Figure 7), on the other hand are tiny specks 
of calcium in the breast. Though microcalcifications may cause more concern 
than macrocalcifications, they don’t automatically mean a positive diagnosis of 
breast cancer. A radiologist will determine the pattern and shape of the 
microcalcifications and if suspicious, a biopsy will be recommended (“American 
Cancer Society | Information and Resources for Cancer: Breast, Colon, Lung, 
Prostate, Skin,” 2016, “Mammograms,” 2014)\ 
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Fig 3. Images Captured in a Standard Mammogram 
Source: (“Mammograms,” 2016) 
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Fig. 4. Mammogram of a macrocalcification in the right breast, a mediolateral 
oblique view ( RMLO)  
Source: (“Siemens USA,” 2016) 
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Fig. 5. Mammogram of a macrocalcification in right breast, a centrocaudal view 
(RCC)  
Source: (“Siemens USA,” 2016) 
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Fig 6. Mammogram of a microcalcification in the right breast, a centrocaudal 
view (RCC)  
Source: (Tse et al., 2008) 
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Fig 7. Mammogram of a microcalcifications in the right breast, a mediolateral 
oblique view (RMLO)  
Source: (Tse et al., 2008) 
 
Masses are the other clinical finding in mammograms, though the 
presence of a mammary mass does automatically mean a diagnosis of breast 
cancer. Fluid-filled masses are usually cysts, and solid masses can be non-
cancerous tumors. So, fluid-filled masses do not usually alarm physicians though 
a finding of a solid mass usually warrants a biopsy. The American Cancer 
Society recommends having all  a woman’s mammograms available to 
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radiologists to make the tracking of breast changes, such as calcifications and 
masses, much easier (“Mammograms,” 2016, “U S Food and Drug 
Administration Home Page,” 2016). 
BI-RADS score 
A BI-RADS, or Breast Imaging Reporting and Data System, is a 
standardized score used by doctors to report mammogram findings. It consists of 
sorting mammogram results into categories that are numbered 0 to 6 which 
makes the communication of results and follow up easier because the same 
words and terms are used across many settings. Category 0 signifies that the 
breast exam is incomplete, while categories 1 through 6 signify that the breast 
exam is complete. Specifically, category 1, category 2, category 3, category 4, 
category 5, and category 6 signify a finding of: negative, benign, benign finding 
with follow-up recommended, suspicious finding with biopsy recommended, 
suggestive of a malignancy, and biopsy-proven malignancy, respectively, Table 
3 (“Early Detection,” 2016, “Mammograms,” 2016).  
 The Bi-RADS also includes a report on breast density. This describes the 
breast tissue in order of increasing breast density. The least dense a breast is, the 
more fat in the breast and the more likely that the mammogram will detect an 
abnormality. Conversely, the more dense a breast is then the harder it is to find 
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cancer with a mammogram as it is possible that the cancer can blend with the 
fibrous breast tissue.  For this reason, if a woman has very dense breast tissue, it 
is the physician’s duty by law to notify the patient and to signal the fatty tissue 
findings in patients’ take-home report (“Early Detection,” 2016, “Mammograms,” 
2016).  
Table 3. BI-RADS score used for mammogram reporting 
Category Definition Meaning 
Category 0 A comparison 
to a prior 
mammogram 
or additional 
imaging might 
be needed. 
The radiologist could be seeing an abnormality, 
but it is not clear and more tests such as spot 
compression (the compression of the breast to a 
smaller area when doing the mammogram,), a 
greatly magnified view, a specialized 
mammogram views, or an ultrasound is needed. 
The doctor should also compare the new 
mammogram with older mammograms to 
determine if there have been changes in the breast 
over time. 
Category 1 Negative The report is negative for masses, abnormal 
structures, and suspicious calcifications. 
Category 2 Non-
cancerous 
finding 
The mammogram is negative as there is no sign of 
breast cancer. The doctor describes a benign 
finding, such as macrocalcifications, so others who 
look at the mammogram will not be alarmed by 
breast structures that suspicious. 
Category 3 Benign 
finding, but 
follow-up is 
recommended 
There is a very high chance that the finding is 
benign, greater than 98%,  but it is has not been 
proven to be benign in nature. It is recommended 
to follow up in 6 months and then regularly to 
confirm the finding is benign. This prevents 
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unnecessary biopsies while still allowing early 
diagnosis by keeping a close watch on a 
suspicious finding 
Category 4 Suspicious 
finding was 
detected and a 
biopsy is 
recommended. 
The finding is not obviously cancer, but the 
radiologist is concerned so a biopsy is 
recommended.  This category is furthered divided 
into: 
4A- The finding has a low probability of being 
cancer 
4B – There is an intermediate probability that the 
breast has a cancer growth 
4C- There is a moderate concern that the breast 
has cancer. 
Category 5 Test suggests a 
malignancy 
The results look like cancer, and have a probability 
of greater than 95% of being cancer. The 
radiologist recommends a biopsy. 
Category 6 Malignancy 
proven 
through 
biopsy 
Category 6 is used for mammograms that have 
been diagnosed as cancer through previous 
biopsies. Mammograms are used in these cases to 
determine how the cancer treatment is working. 
(“Mammograms,” 2016) 
Mammogram Limitations 
 Co-morbid conditions affect the efficacy of mammograms as an important 
screening test. A mammogram may catch cancer in its early stages, but a patient 
may not live longer if she has other life-threatening conditions For this reason, 
the American Cancer Society recommends that women with very serious health 
issues communicate with their doctor to see if it is still necessary to continue 
mammogram testing.  
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In terms of screening, mammograms are the best diagnostic tests available 
for breast cancer prevention.  Nonetheless, there is a still a possibility that the 
mammography will show a false-negative, which means that there doesn’t seem 
to be breast cancer present in breast tissue, but the patient in fact has the disease. 
According to NIH, false negatives occur at the rate of 1 in 5 mammograms 
(“Mammograms,” 2016), but it is important to take into account the unique 
qualities of each person that undergoes a mammogram. 
 A study evaluated mammogram results based on different patient 
characteristics (Kerlikowske et al., 1996;   Rosenberg et al., 1998). Using 
population-based databases and tumor registries, investigators studied the 
effects of age, estrogen replacement therapy, and ethnicity in mammogram 
sensitivity. The authors defined sensitivity as the proportion of patients 
diagnosed with breast cancer that were identified as such in a mammogram, so 
sensitivity is the proportion of cases that are correctly identified as such by the 
screening test. In terms of age, the investigators noted that as women age, they 
are more likely to undergo estrogen replacement therapy, and they hypothesized 
that this might affect the sensitivity of mammograms. A woman’s age and 
ethnicity also impacts their breast density such that the older a woman, the more 
dense the breast tissue. This study found that the sensitivity of mammograms 
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was most reduced with a combination of age and estrogen replacement therapy 
use: The sensitivity was 54% in women that were younger than age 40, 77% in 
women aged 40-49, 78% in women 50-64 years of age, and 85% in women older 
than 64. Moreover, sensitivity was 74% amongst women undergoing estrogen 
replacement and 81% with nonusers. So, women with negative mammograms 
could have the disease if they are younger than 40, have dense breasts, and are 
undergoing HRT (Kerlikowske et al., 1996;   Rosenberg et al., 1998). 
False negative test results are more common in younger women, and this 
has important treatment implications because biochemically, younger women 
have different disease characteristics. A 1999 study by Porter et al. sought out to 
determine the characteristics of tumors that were found through mammograms 
in comparison to tumors not identified by mammograms (Porter et al., 1999). In 
this case-control study involving 379 women, tumors were labeled “interval 
detected” if the cancer was found after a negative mammogram result, and they 
were labeled “screen detected” if the tumor was found after a positive 
mammogram test. Tumors from each group were then evaluated clinically and 
histologically using different biochemical markers. It was determine that 
younger women had tumors that were of a larger size and they also had markers 
indicative of high proliferation rates. In this sense, mammograms are the best 
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screening modality we have, but work needs to be done to improve false-
negatives because they can delay treatment. 
There is also the possibility of a false-positive mammogram where the 
mammogram looks abnormal but the patient does not have cancer, and false-
positives can cause patients stress and anxiety.  For example, it is estimated that 
50% of women getting mammograms over a 10-year period get false-positive test 
results, not to mention that it is more common to get a false positive during a 
woman’s first mammogram.  
Elmore et al. looked to determine the rates of false positive results by 
determining the cumulative risk of a false positive (Elmore et al., 1998). A false 
positive was defined by the authors as “a test that aroused a suspicion of cancer 
and prompted recommendations for extra workup in women in whom whom 
breast cancer was not diagnosed within the following year (Elmore et al., 1998) ”. 
The false positive rate after 10 mammograms was computed at 49%. Moreover, 
one third of the women had abnormal mammograms which required follow, and 
subsequently no breast cancer was found in those cases (Elmore et al., 1998).  
A later study set out to evaluate the performance of radiologists during 
the process of diagnosing breast cancers (Rosenberg et al., 2006). Using breast 
cancer registries, cases were retrospectively analyzed and it was found that recall 
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rates for mammographic studies, or the proportion of times women were called 
back for further testing, was 10%. Thus, an average of 1 in 10 women were called 
back from each mammogram for further testing. From these recall rates, only 4.7 
cancers for every 1000 women were detected (Rosenberg et al., 2006). This study 
uncovered a worryingly small number of cancers for such high recall rates. 
It is important to note that women who have another mammogram for 
comparison decrease their rate of a false positive test result. Hubbard et al. 
sought to determine if biennial screenings would impact the odds of women 
receiving a false positive result on their first mammogram over ten years 
(Hubbard et al., 2011). This prospective cohort-type study analyzed 7 cancer 
registries and enrolled 169,456 women with ages from 40 to 59. This study found 
different false positive rates in women who went biennial screening, and who 
underwent a first screening at age 40. They found a 61% probability of receiving 
a false positive for a first-time mammogram, and this decreased to 41% with 
biennial screening. False positive biopsy recommendations also went down, from 
a 7% probability to a 4.8% probability. So, having multiple results for different 
women through biennial screenings reduces the probability of receiving a false-
positive result and diminishes the chance of undergoing a false-positive induced 
biopsy. (Hubbard et al., 2011). 
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Similar to false-negatives, false-positives also occur in younger women 
because of increased breast density, and are also common in women who have 
had biopsies, are taking estrogen, or who have breast cancer in their family. In 
the case of a false positive, a radiologist will order other tests to ensure the 
reliability of the mammogram. Anxiety from false-positive mammograms is an 
unintended consequence of screening, but over diagnosis can lead to greater 
harm to the patient. 
DCIS and Overtreatment 
 As mentioned before, DCIS, is a collection of cells with abnormalities that 
have not invaded past the breast duct, and women who present with DCIS are 
considered to have a risk factor for invasive breast cancer. However, because of 
the heterogenous nature of DCIS, it is unclear which pathological form of DCIS 
progresses to breast cancer.  
Overdiagnosis is defined by Welch et al. as a cancer that is diagnosed and 
does not cause symptoms or death (Welch & Black, 2010b). It is argued that 
overdiagnosis occurs because cancer is a biologically complex disease that affects 
different people in distinctive manners. Overdiagnosis occurs because a cancer 
never progresses, or the patient dies of a different mortality (Welch & Black, 
2010b). The Welch et al. group also investigated the rates of suggested 
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overtreatment by analyzing well-known randomized control mammogram trials. 
They found that only 1 study provided a 15 year follow up, and from the rates of 
cancer incidence presented in this study they computed an overdiagnosis risk of 
24% (Welch & Black, 2010b). Potentially, almost 1 out of every 4 women could 
suffer from overdiagnosis 
As can be seen, overtreatment is a problem with early screening in breast 
cancer. From the provider’s perspective, it is difficult for doctors to distinguish 
pathologic findings that would pose a significant health concern from a finding 
that will not affect a patient’s health. While treatment is given in relation to each 
specific breast tumor’s characteristics, there does not exist a way to determine 
which cancer will progress. For this reason, when a finding is positive, treatment 
is almost always recommended.  
Mammograms find ductal carcinoma in situ but often, these pathologies 
don’t continue growing and are not a threat to patients’ health. Treatment of 
these benign, yet cancerous looking pathologies leads to overtreatment that 
exposes women to the toxic effects of therapy. As Welch et al. states, false-
positive cases are transitory, but overdiagnosis can affect a patients health and 
well-being (Welch & Black, 2010b).  
Progression rates for DCIS are low despite the fact that women may be 
		 41 
treated. Factors that impact progression of DCIS rates, according to Allegra et al., 
depend on patient characteristics as well as tumor characteristics (Allegra et al., 
2010). An analysis of the SEER database from 1998 to 2003 uncovered important 
factors related to DCIS and prognosis. In general, the younger the age at 
diagnosis of DCIS then the worse the prognosis. If DCIS is discovered because it 
is causing symptoms, there is more threat to a woman’s health as compared to 
DCIS that is detected during a routine screening mammogram. Finally, African 
American women have higher mortality and recurrence rates for DCIS.  
 
DISCUSSION 
Mammograms are the best screening tools available, but based on the 
literature reviewed, it seems that mammograms do not contribute significantly to 
alleviating mortality from breast cancer and are prone to causing medical errors. 
The 2015 ACS screening guidelines reflect up-to-date findings from studies on 
mammograms. Currently, for women with only an average breast cancer risk, 
guidelines dictate that after age 45, women should have regular screening. In the 
45 to 54 age group, women should undergo annual screening exams, and women 
55 and older should receive mammograms twice annually (biennially). Finally, 
clinical breast examinations are not recommended (Oeffinger et al., 2015). The 
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ideal parameters in which mammograms work best to identify DCIS and 
malignant cancer are defined while the limits of mammograms are defined by 
the characteristics of the patient that is screened. 
The ACS currently cannot provide recommendations on overdiagnosis 
because there is a huge gap in the literature on this topic. Rates of overdiagnosis 
range from 5% to 50%, a large range that reflects inaccuracies. The rates were 
computed through either empirical investigations based on observation or 
modeling studies. Both of these types of investigations are prone to biases that 
make them inaccurate, so, no current study provides accurate measurements of 
overdiagnosis rates. Nonetheless, it is evident that overdiagnosis causes 
overtreatment and jeopardizes the women involved (Oeffinger et al., 2015). 
When DCIS is found via mammograms, the goal is to prevent progression 
to an invasive disease. DCIS is considered an early stage cancer, so treatment is 
done locally with surgery, radiation, and hormone therapy. Surgery is done by 
complete removal of the breast, mastectomy, or by a lumpectomy in which only 
the affected portion of the breast is removed. Often, with a lumpectomy, the 
patient receives hormone therapy with tamoxifen and radiation (“Surgery for 
breast cancer,” 2016). This has proven to stop DCIS progression. 
Surgical treatment with mastectomy, though controversial, is an accepted 
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treatment for DCIS. Mastectomy as a treatment is especially crucial for comedo 
type DCIS which has a high recurrence rate and worse prognosis and is 
considered a predictor of recurrence (EORTC Breast Cancer Cooperative Group 
et al., 2006; Fisher et al., 1999; Fonseca et al., 1997b).  
A 1997 study showed that a complete mastectomy of DCIS lead to a 
recurrence rate of 1% (Fonseca et al., 1997b). Subsequent studies sought to 
analyze the efficacy of lumpectomy followed by radiation therapy as well as 
lumpectomy in combination with tamoxifen. It was shown that survival with a 
combination of lumpectomy with radiation therapy increased from 75% with 
lumpectomy alone to 85% with the combination. Another study showed that 
tamoxifen in combination with lumpectomy also decreased breast cancer relapse 
events after 5 years.  So, depending on the DCIS subtype, a combination of 
mastectomy with radiation and tamoxifen can be used to control DCIS 
progression to an invasive form of breast cancer (EORTC Breast Cancer 
Cooperative Group et al., 2006; Fisher et al., 1999; Fonseca et al., 1997b). 
It is encouraging that DCIS can be stopped from progressing to an 
invasive cancer through these scientifically backed studies. However, given the 
overtreatment rates, breast cancer patients suffer when they are overdiagnosed. 
Patients that undergo mastectomy and lumpectomy can suffer from 
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psychological issues involving impaired body image and sexuality. Radiation 
therapy on the other hand causes debilitating toxicity that presents with 
depression, dermatitis, cardiovascular disease, and fatigue, while tamoxifen can 
cause cramps, fatigue, and vaginitis (Glassey, Ives, Saunders, & Musiello, 2016; 
Hall et al., 2016; Love, 1989). So more work needs to be done to delineate the 
factors that dictate the evolution of DCIS to malignant breast cancer 
biochemically. In this manner, the risks of overtreatment can be diminished 
because the molecular switches that dictate the transition to malignancy would 
be established, and there would be set guidelines recommending treatments for 
DCIS cases with the molecular signatures known to progress to malignancy.  
Currently, only some tumor markers are used to guide therapeutic 
decisions. ASCO recommends measuring the estrogen receptor (ER) and 
progesterone receptor (PR) status of primary and metastatic lesions. If a tumor is 
positive for the hormone receptors for estrogen and progesterone, around 1/3 of 
tumors, then it is highly likely that the hormone is helping the tumor grow. In 
these cases, drugs that mimic the hormone and block the receptor are used as 
treatment before the patient undergoes chemotherapy and they are also used 
after chemo as well (Harris et al., 2007; Poznak et al., 2015; “Targeted therapy for 
breast cancer,” 2014) 
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HER2  is also used to determine the cancers prognosis based on the 
protein’s overexpression and amplification profile. Approximately 20% of 
cancers are HER2 receptor positive which allows the cancer to spread 
aggressively, and the more protein in cancer cells the worse the prognosis.  For 
HER2 + tumors, therapies that target the receptor have been successful and 
dictate administration of Trastuzumab, an antibody that blocks the protein 
preventing it from carrying out its mechanism of action (Harris et al., 2007; 
Poznak et al., 2015; “Targeted therapy for breast cancer,” 2014). 
 The HER2, ER, and PR status of a tumor can be analyzed by genomic tests 
that measure the activity of certain genes from a section of tissue.  However, 
these tests are only recommended for cancers in stage 1 or higher. If we consider 
the gene profile of DCIS, we can extend molecular diagnosis that are normally 
used in stage 1 cancers. This would be a novel testing method because currently, 
no gene analysis arrays exist for stage 0 cancers. This innovation would prevent 
overdiagnosis and unnecessary treatments by ensuring only that DCIS cases that 
have the potential for invading are the only cases treated. The assay would be 
more accurate than mammograms because the test would not be influenced by 
the patient’s individual factors unlike mammograms. 
 DCIS progression involves the penetration of cells into the duct and to 
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other tissues outside the breast. It has been found that epithelial cells from DCIS 
and epithelial cells from an invasive form of the disease have negligible 
molecular differences. So, it seems that the biochemically the potential to 
transition to an invasive form exists even in the DCIS form. The cancer invades 
and becomes harder treat only when the molecules are expressed (Carraro, Elias, 
& Andrade, 2014; Castro et al., 2008).  
 Implicated in this transition are genes involved in cell proliferation, 
motility, and growth. E-Cadherin (CDH1) is involved in cell adhesion, and 
silencing of this protein has been found to be cause cellular dedifferentiation, 
invasiveness, and poor prognosis. Though the mechanism by which CDH1 is lost 
is not clear, it seems to involve repression of the proteins transcription as a result 
of hypermethylation of its promoter (Carraro et al., 2014; Castro et al., 2008) 
 Matrix remodeling proteins( MMP) have also been found to turn on 
malignancy.  MMP’s allow cells to break down the basement membrane that 
keeps the cells inside the breast. Loss of the basement membrane takes away the 
barrier and facilitates migration and invasion. This involves demethylation and 
expansion of the genes that code for MMPs so that the protein is upregulated 
abnormally (Carraro et al., 2014; Castro et al., 2008). 
 MMP’s and CDH1 are just a few genes that might be important drivers of 
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malignancy in DCI. However, it is evident from the literature that there has not 
been enough work in this area. There are not enough DCIS samples to analyze 
and there are no studies to relate DCIS molecular characteristics to long-term 
malignancy rates because a finding of DCIS automatically leads to a decision to 
treat though it may not be warranted (Carraro et al., 2014; Castro et al., 2008). 
The future of cancer care is dictating a move towards more cost-effective 
treatments, and a genomic assay for stage 0 cancer would fit into this category. In 
2016, The Center for Medicaid and Medicare (CMS) innovation centers imposed 
the Oncology Care Model in an attempt to stimulate “better care, smarter 
spending, and healthier people” (Medicare, Boulevard, Baltimore, Baltimore, & 
Usa, 2016). Based on the high re-test rate for mammograms, genomic tests would 
only have to be performed once because of the fact that the biochemical changes 
that drive DCIS are already present in the cells, as discussed above. Also, as 
shown by the high re-test and inaccuracy rates, DCIS genomic tests would be 
more accurate and prevent overspending as the chance of being called back, 
false-positive, and false-negative rates would be reduced. Work needs to start to 
investigate the possibility of development of such a test that would improve 
breast cancer screening. 	  
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